Squarepoint
CRSP icon

Squarepoint’s CRISPR Therapeutics CRSP Stock Holding History

Squarepoint’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6M Buy
286,789
+133,214
+87% +$7.02M 0.02% 826
2026
Q1 		$7.31M Sell
153,575
-427,533
-74% -$22.5M 0.01% 1256
2025
Q4 		$30.5M Buy
+581,108
New +$34.8M 0.03% 571
2025
Q3 		– Sell
-30,278
Closed -$1.74M – 4450
2025
Q2 		$1.47M Sell
30,278
-42,746
-59% -$1.65M ﹤0.01% 2325
2025
Q1 		$2.49M Sell
73,024
-93,115
-56% -$3.95M ﹤0.01% 1916
2024
Q4 		$6.54M Sell
166,139
-82,840
-33% -$3.91M 0.01% 1431
2024
Q3 		$11.7M Sell
248,979
-19,844
-7% -$1.01M 0.02% 881
2024
Q2 		$14.5M Sell
268,823
-5,207
-2% -$301K 0.02% 738
2024
Q1 		$18.7M Buy
274,030
+146,672
+115% +$10.5M 0.03% 646
2023
Q4 		$7.97M Sell
127,358
-17,719
-12% -$980K 0.02% 1079
2023
Q3 		$6.59M Buy
145,077
+17,665
+14% +$912K 0.02% 1011
2023
Q2 		$7.15M Sell
127,412
-3,506
-3% -$199K 0.02% 869
2023
Q1 		$5.92M Sell
130,918
-35,516
-21% -$1.72M 0.02% 794
2022
Q4 		$6.77M Buy
166,434
+96,783
+139% +$5.13M 0.03% 683
2022
Q3 		$4.55M Buy
+69,651
New +$5.05M 0.02% 816
2021
Q3 		– Sell
-5,400
Closed -$874K – 2990
2021
Q2 		$874K Sell
5,400
-6,452
-54% -$785K ﹤0.01% 1734
2021
Q1 		$1.44M Buy
11,852
+6,797
+134% +$1.03M 0.01% 1267
2020
Q4 		$774K Buy
+5,055
New +$597K 0.01% 1491
2020
Q2 		– Sell
-13,533
Closed -$574K – 2269
2020
Q1 		$574K Sell
13,533
-43,352
-76% -$2.24M 0.01% 966
2019
Q4 		$3.46M Buy
+56,885
New +$3.11M 0.02% 632
2019
Q3 		– Sell
-6,348
Closed -$299K – 2388
2019
Q2 		$299K Buy
6,348
+494
+8% +$19.7K ﹤0.01% 1933
2019
Q1 		$209K Sell
5,854
-14,496
-71% -$501K ﹤0.01% 1930
2018
Q4 		$581K Buy
+20,350
New +$707K 0.01% 1170
2018
Q2 		– Sell
-7,919
Closed -$362K – 1785
2018
Q1 		$362K Buy
+7,919
New +$327K 0.01% 1224

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint's CRSP Position: Q2 2026 in Review

Squarepoint increased its CRISPR Therapeutics (CRSP) stake by 87% in Q2 2026, buying an estimated $7.02M and bringing the position to 286,789 shares worth $15.6M. The position accounts for 0.02% of the portfolio, ranked #826.

Squarepoint first reported a position in CRSP in Q1 2018 and has held it in 24 quarters since. The position peaked at $30.5M in Q4 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Squarepoint held 286,789 shares of CRISPR Therapeutics worth $15.6M as of Q2 2026.
  • Squarepoint bought 133,214 CRISPR Therapeutics shares in Q2 2026, an estimated $7.02M.
  • CRISPR Therapeutics made up 0.02% of Squarepoint's portfolio in Q2 2026, its #826 holding.
  • Squarepoint first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 24 quarters since.
  • Squarepoint's CRISPR Therapeutics position peaked at $30.5M in Q4 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.